Immune-mediated mechanisms of antimetastatic effect the carcinoma-specific transfer factor in conditions of growth of experimental tumours at mice C57BL/6

Summary. The submitted experimental data testify to perspectivity of a method of prevention of metastasises by active formation of antineoplastic immune protection of an organism by the transfer factor (TF), specific to cells of a certain tumour. Adjuvant immunotherapy by carcinoma-specific TF prevents occurrence of lung metastasises Lewis lung carcinoma (LLC) at 50% of mice C57BL/6 and suppresses growth of already developed metastasises in 75% of cases (at adjuvant therapy nonspecific TF — 22 and 29% accordingly). Use of carcinoma-specific TF at mice C57BL/6 after removal of melanoma В16 prevents of metastasises only at 11% of animals, and at others — suppresses growth lung metastasises on 70% (at adjuvant therapy nonspecific TF — 14 and 56% accordingly), that testifies for the benefit of conformity carcinoma-specific TF to LLC antigenic structure. It is established, that tumor-specific TF is capable to transfer immune reactivity on antigens of this tumour to the recipient, to initiate for short time development of the productive immune answer of an organism on tumoral growth and to prevent or inhibit dissemination tumoral process that is a basis for the further development of this direction of biotherapy of cancer patients with the purpose of increase of efficiency of the basic methods of their treatment.